Respondents who felt more negative were concerned about increasing costs associated with research and development (R&D), logistics, supply chains etc.
More than half of the surveyed healthcare industry professionals indicated that their sentiment on the impact of Brexit on the UK’s healthcare sector became more negative, according to a survey* by GlobalData.
The data and analytics company notes that 54 per cent of healthcare industry professionals in the survey believed that their sentiment worsened three years after Brexit.
GlobalData’s latest Thematic Intelligence report, ‘Brexit and the Healthcare Industry 2023’, reveals that the largest proportions of respondents that felt more negative of Brexit were based in the UK (71 per cent) and the EU (70 per cent).
Elton Kwok, Market Research Manager in Pharma, GlobalData comments, “Previous Brexit survey conducted by GlobalData in 2021 found that the majority of respondents’ sentiment was more neutral, with 61% of surveyed respondents expressing their sentiment remained the same, when the EU–UK Trade and Cooperation Agreement was reached at the end of 2020.”
Kwok concludes, “Respondents who felt more negative were concerned about increasing costs associated with research and development (R&D), logistics, supply chains, difficulties in accessing research funding and attracting talent, and the failure of the government to enhance the National Health Service (NHS). On the other hand, those with positive sentiment appreciated a more flexible approach to drug regulation and approval post-Brexit.”
* GlobalData survey consisted of 120 healthcare industry professionals surveyed between February 9, 2023 – March 6, 2023.